CSTL Valuation

Castle Biosciences Inc

Add to Watchlist

Advanced Chart

20.560

+0.47(2.339%)1D

Overview
Forecast
Valuation
Earnings

CSTL Relative Valuation

CSTL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CSTL is overvalued; if below, it's undervalued.

Historical Valuation

Castle Biosciences Inc (CSTL) is now in the Fair zone, suggesting that its current forward PS ratio of 1.99 is considered Fairly compared with the five-year average of -29.03. The fair price of Castle Biosciences Inc (CSTL) is between 8.97 to 113.57 according to relative valuation methord.

Relative Value

Fair Zone

8.97-113.57

Current Price：20.56

Fair

-8.97

Trailing

Forward

-43.73

EV/EBITDA

Castle Biosciences Inc. (CSTL) has a current EV/EBITDA of -43.73. The 5-year average EV/EBITDA is -22.07. The thresholds are as follows: Strongly Undervalued below -86.26, Undervalued between -86.26 and -54.17, Fairly Valued between 10.02 and -54.17, Overvalued between 10.02 and 42.11, and Strongly Overvalued above 42.11. The current Forward EV/EBITDA of -43.73 falls within the Historic Trend Line -Fairly Valued range.

-4.41

EV/EBIT

Castle Biosciences Inc. (CSTL) has a current EV/EBIT of -4.41. The 5-year average EV/EBIT is -28.11. The thresholds are as follows: Strongly Undervalued below -162.26, Undervalued between -162.26 and -95.19, Fairly Valued between 38.96 and -95.19, Overvalued between 38.96 and 106.04, and Strongly Overvalued above 106.04. The current Forward EV/EBIT of -4.41 falls within the Historic Trend Line -Fairly Valued range.

1.99

Castle Biosciences Inc. (CSTL) has a current PS of 1.99. The 5-year average PS is 6.92. The thresholds are as follows: Strongly Undervalued below -5.75, Undervalued between -5.75 and 0.58, Fairly Valued between 13.25 and 0.58, Overvalued between 13.25 and 19.59, and Strongly Overvalued above 19.59. The current Forward PS of 1.99 falls within the Historic Trend Line -Fairly Valued range.

28.43

P/OCF

Castle Biosciences Inc. (CSTL) has a current P/OCF of 28.43. The 5-year average P/OCF is -12.92. The thresholds are as follows: Strongly Undervalued below -104.49, Undervalued between -104.49 and -58.70, Fairly Valued between 32.86 and -58.70, Overvalued between 32.86 and 78.64, and Strongly Overvalued above 78.64. The current Forward P/OCF of 28.43 falls within the Historic Trend Line -Fairly Valued range.

353.20

P/FCF

Castle Biosciences Inc. (CSTL) has a current P/FCF of 353.20. The 5-year average P/FCF is -1.54. The thresholds are as follows: Strongly Undervalued below -180.69, Undervalued between -180.69 and -91.12, Fairly Valued between 88.04 and -91.12, Overvalued between 88.04 and 177.62, and Strongly Overvalued above 177.62. The current Forward P/FCF of 353.20 falls within the Strongly Overvalued range.

Castle Biosciences Inc (CSTL) has a current Price-to-Book (P/B) ratio of 1.28. Compared to its 3-year average P/B ratio of 1.49 , the current P/B ratio is approximately -14.11% higher. Relative to its 5-year average P/B ratio of 2.41, the current P/B ratio is about -46.84% higher. Castle Biosciences Inc (CSTL) has a Forward Free Cash Flow (FCF) yield of approximately 5.93%. Compared to its 3-year average FCF yield of -2.48%, the current FCF yield is approximately -338.96% lower. Relative to its 5-year average FCF yield of -2.12% , the current FCF yield is about -379.40% lower.

1.28

P/B

Median3y

1.49

Median5y

2.41

5.93

FCF Yield

Median3y

-2.48

Median5y

-2.12

Competitors Valuation Multiple

The average P/S ratio for CSTL's competitors is 1.76, providing a benchmark for relative valuation. Castle Biosciences Inc Corp (CSTL) exhibits a P/S ratio of 1.99, which is 13.50% above the industry average. Given its robust revenue growth of -0.94%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CSTL.O

Castle Biosciences Inc

Organogenesis Holdings Inc

Performance Decomposition

Market capitalization of CSTL decreased by 30.70% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -50.60 to -60.22.

The secondary factor is the Revenue Growth, contributed -0.94%to the performance.

Overall, the performance of CSTL in the past 1 year is driven by P/E Change. Which is more unsustainable.

-0.94%

87.00M → 86.19M

Revenue Growth

-48.78%

10.25 → 5.25

Margin Expansion

19.02%

-50.60 → -60.22

P/E Change

-30.70%